Zevra is a rare disease therapeutics company driven by science, data and patient need to create transformational therapies for diseases with limited or no treatment options.
Visit www.KeepZevraStrong.com for more on voting the WHITE card in support of Zevra’s plan for value creation at the upcoming 2023 Annual Meeting of Stockholders.
With an understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed.
By letting data tell its unbiased story, our transparent narratives have overcome complex development challenges to produce needed medicines.
Nimble and dauntless, we push boundaries beyond what is possible to advance new therapies that meaningfully improve patients’ lives.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
